세계의 폐경후 골다공증 치료 시장 : 시장 규모, 점유율, 동향 분석(약제 클래스별, 유형별, 유통 채널별, 지역별), 부문별 예측(2025-2030년)

Postmenopausal Osteoporosis Treatment Market Growth & Trends:

The global postmenopausal osteoporosis treatment market size is expected to reach USD 13.7 billion by 2030 and is expected to expand at a CAGR of 4.6% from 2025 to 2030, according to a new report by Grand View Research, Inc. The market has grown significantly as a result of the growing geriatric population and lifestyle changes. As the older population is more susceptible, their population growth is anticipated to be a major driving force behind the market expansion. For instance, the number of people aged 60 years and above is predicted to rise from 1 billion in 2020 to 1.4 billion by 2030 and 2.1 billion by 2050, according to the World Health Organization's October 2021 report. As a result, the market is anticipated to expand during the forecast period due to a rise in demand for postmenopausal osteoporosis treatment among older people.

In addition, lifestyle modifications like inactivity, excessive alcohol consumption, smoking, long work hours, and unhealthy eating patterns have an impact on menopause and increase the risk of osteoporosis in many women around the globe. Furthermore, age, smoking, alcohol consumption, and the use of drugs to address illnesses like gonadotropins, excessive thyroid hormone use, & cytotoxic agents are a few of the risk factors that can lead to low bone density and the development of the condition in women after menopause. Thus, it will drive the market growth. In 2021, more than 200 million women were affected with osteoporosis, and 1 in 3 women over 50 years of age are predicted to sustain an osteoporosis fracture, according to statistics from the International Menopause Society (IMS). As a result of the aforementioned factors, it is anticipated that the studied market will expand over the projected period.

However, it is anticipated that during the projection era, low awareness about the disease will impede industry growth. In the forecast period, there will likely be a significant increase in research and development efforts as a result of investments made by industry participants and research institutions. For instance, according to the information posted on clinicaltrial.gov, as of June 2021, there were approximately 25 ongoing phase III as well as phase IV clinical trials for osteoporosis medications in the U.S. Consequently, as a result of the aforementioned factors, the market is expected to grow over the forecast period. For instance, Eli Lilly and Company is creating blosozumab, a humanized IgG4 monoclonal antibody, to treat postmenopausal osteoporosis. It is an inhibitor of the SOST protein and is presently undergoing phase II clinical studies.

Postmenopausal Osteoporosis Treatment Market Report Highlights:

• Branded osteoporosis drugs dominated the market, accounting for a share of 54.0% in 2024. These medications are widely used due to their proven effectiveness, regulatory approvals, and strong market presence.
• Retail pharmacies dominated the market in 2024. The growing geriatric population and the increasing prevalence of osteoporosis have been key factors driving the demand for medications through this distribution channel.
• North America held the largest share in 2024 due to the strong presence of key market participants, as well as rising R&D spending and federal assistance, in the region
• Asia Pacific is expected to grow at the highest CAGR over the projected period due to the rising prevalence of target disease, the growing aging population, and the increasing adoption of postmenopausal osteoporosis treatments

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Drug Class
  • 1.2.2. Type
  • 1.2.3. Distribution Channel
• 1.3. Estimates and Forecast Timeline
• 1.4. Research Methodology
• 1.5. Information Procurement
  • 1.5.1. Purchased Database
  • 1.5.2. GVR's Internal Database
  • 1.5.3. Secondary Sources
  • 1.5.4. Primary Research
• 1.6. Information Analysis
  • 1.6.1. Data Analysis Models
• 1.7. Market Formulation & Data Visualization
• 1.8. Model Details
  • 1.8.1. Commodity Flow Analysis
• 1.9. List of Secondary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Postmenopausal Osteoporosis Treatment Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
  • 3.2.2. Market Restraint Analysis
• 3.3. Business Environment Analysis
  • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
    • 3.3.1.1. Supplier Power
    • 3.3.1.2. Buyer Power
    • 3.3.1.3. Substitution Threat
    • 3.3.1.4. Threat of New Entrants
    • 3.3.1.5. Competitive Rivalry
  • 3.3.2. PESTLE Analysis

Chapter 4. Postmenopausal Osteoporosis Treatment Market: Drug Class Business Analysis

• 4.1. Drug Class Market Share, 2024 & 2030
• 4.2. Drug Class Segment Dashboard
• 4.3. Market Size & Forecasts and Trend Analysis, by Drug Class, 2018 to 2030 (USD Million)
• 4.4. Branded
  • 4.4.1. Branded Market, 2018 - 2030 (USD Million)
• 4.5. Generics
  • 4.5.1. Generics Market, 2018 - 2030 (USD Million)

Chapter 5. Postmenopausal Osteoporosis Treatment Market: Type Business Analysis

• 5.1. Type Market Share, 2024 & 2030
• 5.2. Type Segment Dashboard
• 5.3. Market Size & Forecasts and Trend Analysis, by Type, 2018 to 2030 (USD Million)
• 5.4. Bisphosphonates
  • 5.4.1. Bisphosphonates Market, 2018 - 2030 (USD Million)
• 5.5. Parathyroid Hormone Therapy
  • 5.5.1. Parathyroid Hormone Therapy Market, 2018 - 2030 (USD Million)
• 5.6. Calcitonin
  • 5.6.1. Calcitonin Market, 2018 - 2030 (USD Million)
• 5.7. Selective Estrogen Inhibitors Modulator (SERM)
  • 5.7.1. Selective Estrogen Inhibitors Modulator (SERM) Market, 2018 - 2030 (USD Million)
• 5.8. Rank Ligand Inhibitors
  • 5.8.1. Rank Ligand Inhibitors Market, 2018 - 2030 (USD Million)
• 5.9. Other Products
  • 5.9.1. Other Products Market, 2018 - 2030 (USD Million)

Chapter 6. Postmenopausal Osteoporosis Treatment Market: Distribution Channel Business Analysis

• 6.1. Distribution Channel Market Share, 2024 & 2030
• 6.2. Distribution Channel Segment Dashboard
• 6.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2018 to 2030 (USD Million)
• 6.4. Hospital Pharmacies
  • 6.4.1. Hospital Pharmacies Market, 2018 - 2030 (USD Million)
• 6.5. Retail Pharmacies
  • 6.5.1. Retail Pharmacies Market, 2018 - 2030 (USD Million)
• 6.6. Online Pharmacies
  • 6.6.1. Online Pharmacies Market, 2018 - 2030 (USD Million)

Chapter 7. Postmenopausal Osteoporosis Treatment Market: Regional Estimates & Trend Analysis

• 7.1. Regional Market Share Analysis, 2024 & 2030
• 7.2. Regional Market Dashboard
• 7.3. Market Size & Forecasts Trend Analysis, 2018 to 2030:
• 7.4. North America
  • 7.4.1. North America Postmenopausal Osteoporosis Treatment Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
  • 7.4.2. U.S.
    • 7.4.2.1. Key Country Dynamics
    • 7.4.2.2. Regulatory Framework
    • 7.4.2.3. Competitive Insights
    • 7.4.2.4. U.S. Postmenopausal Osteoporosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.4.3. Canada
    • 7.4.3.1. Key Country Dynamics
    • 7.4.3.2. Regulatory Framework
    • 7.4.3.3. Competitive Insights
    • 7.4.3.4. Canada Postmenopausal Osteoporosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.4.4. Mexico
    • 7.4.4.1. Key Country Dynamics
    • 7.4.4.2. Regulatory Framework
    • 7.4.4.3. Competitive Insights
    • 7.4.4.4. Mexico Postmenopausal Osteoporosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
• 7.5. Europe
  • 7.5.1. Europe Postmenopausal Osteoporosis Treatment Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
  • 7.5.2. UK
    • 7.5.2.1. Key Country Dynamics
    • 7.5.2.2. Regulatory Framework
    • 7.5.2.3. Competitive Insights
    • 7.5.2.4. UK Postmenopausal Osteoporosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.5.3. Germany
    • 7.5.3.1. Key Country Dynamics
    • 7.5.3.2. Regulatory Framework
    • 7.5.3.3. Competitive Insights
    • 7.5.3.4. Germany Postmenopausal Osteoporosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.5.4. France
    • 7.5.4.1. Key Country Dynamics
    • 7.5.4.2. Regulatory Framework
    • 7.5.4.3. Competitive Insights
    • 7.5.4.4. France Postmenopausal Osteoporosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.5.5. Italy
    • 7.5.5.1. Key Country Dynamics
    • 7.5.5.2. Regulatory Framework
    • 7.5.5.3. Competitive Insights
    • 7.5.5.4. Italy Postmenopausal Osteoporosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.5.6. Spain
    • 7.5.6.1. Key Country Dynamics
    • 7.5.6.2. Regulatory Framework
    • 7.5.6.3. Competitive Insights
    • 7.5.6.4. Spain Postmenopausal Osteoporosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.5.7. Norway
    • 7.5.7.1. Key Country Dynamics
    • 7.5.7.2. Regulatory Framework
    • 7.5.7.3. Competitive Insights
    • 7.5.7.4. Norway Postmenopausal Osteoporosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.5.8. Denmark
    • 7.5.8.1. Key Country Dynamics
    • 7.5.8.2. Regulatory Framework
    • 7.5.8.3. Competitive Insights
    • 7.5.8.4. Denmark Postmenopausal Osteoporosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.5.9. Sweden
    • 7.5.9.1. Key Country Dynamics
    • 7.5.9.2. Regulatory Framework
    • 7.5.9.3. Competitive Insights
    • 7.5.9.4. Sweden Postmenopausal Osteoporosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
• 7.6. Asia Pacific
  • 7.6.1. Asia Pacific Postmenopausal Osteoporosis Treatment Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
  • 7.6.2. Japan
    • 7.6.2.1. Key Country Dynamics
    • 7.6.2.2. Regulatory Framework
    • 7.6.2.3. Competitive Insights
    • 7.6.2.4. Japan Postmenopausal Osteoporosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.6.3. China
    • 7.6.3.1. Key Country Dynamics
    • 7.6.3.2. Regulatory Framework
    • 7.6.3.3. Competitive Insights
    • 7.6.3.4. China Postmenopausal Osteoporosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.6.4. India
    • 7.6.4.1. Key Country Dynamics
    • 7.6.4.2. Regulatory Framework
    • 7.6.4.3. Competitive Insights
    • 7.6.4.4. India Postmenopausal Osteoporosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.6.5. South Korea
    • 7.6.5.1. Key Country Dynamics
    • 7.6.5.2. Regulatory Framework
    • 7.6.5.3. Competitive Insights
    • 7.6.5.4. South Korea Postmenopausal Osteoporosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.6.6. Australia
    • 7.6.6.1. Key Country Dynamics
    • 7.6.6.2. Regulatory Framework
    • 7.6.6.3. Competitive Insights
    • 7.6.6.4. Australia Postmenopausal Osteoporosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.6.7. Thailand
    • 7.6.7.1. Key Country Dynamics
    • 7.6.7.2. Regulatory Framework
    • 7.6.7.3. Competitive Insights
    • 7.6.7.4. Thailand Postmenopausal Osteoporosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
• 7.7. Latin America
  • 7.7.1. Latin America Postmenopausal Osteoporosis Treatment Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
  • 7.7.2. Brazil
    • 7.7.2.1. Key Country Dynamics
    • 7.7.2.2. Regulatory Framework
    • 7.7.2.3. Competitive Insights
    • 7.7.2.4. Brazil Postmenopausal Osteoporosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.7.3. Argentina
    • 7.7.3.1. Key Country Dynamics
    • 7.7.3.2. Regulatory Framework
    • 7.7.3.3. Competitive Insights
    • 7.7.3.4. Argentina Postmenopausal Osteoporosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
• 7.8. MEA
  • 7.8.1. MEA Postmenopausal Osteoporosis Treatment Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
  • 7.8.2. South Africa
    • 7.8.2.1. Key Country Dynamics
    • 7.8.2.2. Regulatory Framework
    • 7.8.2.3. Competitive Insights
    • 7.8.2.4. South Africa Postmenopausal Osteoporosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.8.3. Saudi Arabia
    • 7.8.3.1. Key Country Dynamics
    • 7.8.3.2. Regulatory Framework
    • 7.8.3.3. Competitive Insights
    • 7.8.3.4. Saudi Arabia Postmenopausal Osteoporosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.8.4. UAE
    • 7.8.4.1. Key Country Dynamics
    • 7.8.4.2. Regulatory Framework
    • 7.8.4.3. Competitive Insights
    • 7.8.4.4. UAE Postmenopausal Osteoporosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.8.5. Kuwait
    • 7.8.5.1. Key Country Dynamics
    • 7.8.5.2. Regulatory Framework
    • 7.8.5.3. Competitive Insights
    • 7.8.5.4. Kuwait Postmenopausal Osteoporosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Participant Overview
• 8.2. Company Market Position Analysis
• 8.3. Company Categorization
• 8.4. Strategy Mapping
• 8.5. Company Profiles/Listing
  • 8.5.1. Amgen Inc.
    • 8.5.1.1. Overview
    • 8.5.1.2. Financial Performance
    • 8.5.1.3. Product Benchmarking
    • 8.5.1.4. Strategic Initiatives
  • 8.5.2. Eli Lilly and Company
    • 8.5.2.1. Overview
    • 8.5.2.2. Financial Performance
    • 8.5.2.3. Product Benchmarking
    • 8.5.2.4. Strategic Initiatives
  • 8.5.3. Merck & Co., Inc.
    • 8.5.3.1. Overview
    • 8.5.3.2. Financial Performance
    • 8.5.3.3. Product Benchmarking
    • 8.5.3.4. Strategic Initiatives
  • 8.5.4. Novartis AG
    • 8.5.4.1. Overview
    • 8.5.4.2. Financial Performance
    • 8.5.4.3. Product Benchmarking
    • 8.5.4.4. Strategic Initiatives
  • 8.5.5. Pfizer Inc.
    • 8.5.5.1. Overview
    • 8.5.5.2. Financial Performance
    • 8.5.5.3. Product Benchmarking
    • 8.5.5.4. Strategic Initiatives
  • 8.5.6. AbbVie Inc.
    • 8.5.6.1. Overview
    • 8.5.6.2. Financial Performance
    • 8.5.6.3. Product Benchmarking
    • 8.5.6.4. Strategic Initiatives
  • 8.5.7. Cipla
    • 8.5.7.1. Overview
    • 8.5.7.2. Financial Performance
    • 8.5.7.3. Product Benchmarking
    • 8.5.7.4. Strategic Initiatives
  • 8.5.8. Teva Pharmaceutical Industries Ltd.
    • 8.5.8.1. Overview
    • 8.5.8.2. Financial Performance
    • 8.5.8.3. Product Benchmarking
    • 8.5.8.4. Strategic Initiatives
  • 8.5.9. F. Hoffmann-La Roche Ltd
    • 8.5.9.1. Overview
    • 8.5.9.2. Financial Performance
    • 8.5.9.3. Product Benchmarking
    • 8.5.9.4. Strategic Initiatives